The NIH Funding to Incidence Ratio for Oral Cancer is the lowest among the studied cancer types ($785 for oral cancer as opposed to $2,902 for Breast Cancer). But the incidence of HPV+ Oral Cancer has been projected to increase until 2060. Immunotherapy has shown great promise. But the OC patient response to checkpoint inhibition is low. Future research programs to characterize immunosuppression in oral cancer and to develop personalized immune-modulating technologies are in urgent need.
Comment No. 77